Skip to content
Screener

Ginkgo Bioworks DNA Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$19.5MMiss by $23.5M
EPS-$1.28Miss by $0.07
Revenue estimate$42.9M
EPS estimate-$1.21

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate-$0.58

Financials

Q1 2026

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$379.6M+14.8%
Enterprise value$601.63M+46.8%
P/S2.9×+1.4×

Profitability

See full
Operating margin-221.9%+22.0pp
Net margin-232.6%+31.8pp
FCF margin-128.6%-17.1pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Segments

By segment

See full
Reportable Segment$19.5M—

FAQ

When did Ginkgo Bioworks report Q1 2026 earnings?
Ginkgo Bioworks (DNA) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Ginkgo Bioworks's Q1 2026 revenue and EPS?
Ginkgo Bioworks reported revenue of $19.5M and eps of $-1.28 for Q1 2026.
Did Ginkgo Bioworks beat estimates in Q1 2026?
Revenue missed the consensus estimate of $42.9M by $23.5M. EPS missed the consensus estimate of $-1.21 by $0.07.
How did Ginkgo Bioworks's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 59.7% from $48.3M a year earlier and eps grew 19.0% from $-1.58.
Where can I find Ginkgo Bioworks's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-032093) and the 10-Q periodic report (0001628280-26-032116) directly on SEC EDGAR. The filing index links above go to sec.gov.